AAAAAA

   
Results: 1-9 |
Results: 9
Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in mice
Authors: Mohr, L Yoon, SK Eastman, SJ Chu, Q Scheule, RK Scaglioni, PP Geissler, M Heintges, T Blum, HE Wands, JR
Citation: L. Mohr et al., Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in mice, HUM GENE TH, 12(7), 2001, pp. 799-809
A randomized, double-blind trial comparing pegylated interferon alfa-2b tointerferon alfa-2b as initial treatment for chronic hepatitis C
Authors: Lindsay, KL Trepo, C Heintges, T Shiffman, ML Gordon, SC Hoefs, JC Schiff, ER Goodman, ZD Laughlin, M Yao, RJ Albrecht, JK
Citation: Kl. Lindsay et al., A randomized, double-blind trial comparing pegylated interferon alfa-2b tointerferon alfa-2b as initial treatment for chronic hepatitis C, HEPATOLOGY, 34(2), 2001, pp. 395-403
Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B
Authors: Heintges, T Petry, W Kaldewey, M Erhardt, A Wend, UC Gerlich, WH Niederau, C Haussinger, D
Citation: T. Heintges et al., Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B, DIG DIS SCI, 46(4), 2001, pp. 901-906
Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor
Authors: Heintges, T Encke, J Putlitz, JZ Wands, JR
Citation: T. Heintges et al., Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor, J MED VIROL, 65(4), 2001, pp. 671-680
Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B
Authors: Erhardt, A Reineke, U Blondin, D Gerlich, WH Adams, O Heintges, T Niederau, C Haussinger, D
Citation: A. Erhardt et al., Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B, HEPATOLOGY, 31(3), 2000, pp. 716-725
Antiviral therapy of hepatitis C
Authors: Erhardt, A Petry, W Ebel, M Jablonowski, H Heintges, T Haussinger, D
Citation: A. Erhardt et al., Antiviral therapy of hepatitis C, Z GASTROENT, 38(3), 2000, pp. 259-269
New developments in the therapy of chronic hepatitis B. What are the indications for nucleoside analogues?
Authors: Petry, W Erhardt, A Heintges, T Haussinger, D
Citation: W. Petry et al., New developments in the therapy of chronic hepatitis B. What are the indications for nucleoside analogues?, Z GASTROENT, 38(1), 2000, pp. 77-87
Characterization and binding of intracellular antibody fragments to the hepatitis C virus core protein
Authors: Heintges, T Putlitz, JZ Wands, JR
Citation: T. Heintges et al., Characterization and binding of intracellular antibody fragments to the hepatitis C virus core protein, BIOC BIOP R, 263(2), 1999, pp. 410-418
Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
Authors: Niederau, C Lange, S Heintges, T Erhardt, A Buschkamp, M Hurter, D Nawrocki, M Kruska, L Hensel, F Petry, W Haussinger, D
Citation: C. Niederau et al., Prognosis of chronic hepatitis C: Results of a large, prospective cohort study, HEPATOLOGY, 28(6), 1998, pp. 1687-1695
Risultati: 1-9 |